Patents by Inventor Satyamaheshwar Peddibhotla
Satyamaheshwar Peddibhotla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11905268Abstract: Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.Type: GrantFiled: August 12, 2019Date of Patent: February 20, 2024Assignees: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Otto Phanstiel, IV, Holly Moots, Patrick Maloney, Paul Hershberger, Satyamaheshwar Peddibhotla
-
Publication number: 20230203025Abstract: In some embodiments, the present disclosure provides a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound of Formula (I), and methods of treating, e.g., metabolic diseases using the compound of Formula (I) are also provided.Type: ApplicationFiled: May 28, 2021Publication date: June 29, 2023Inventors: John C. Burnett, Jr., Jeson Sangaralingham, Siobhan Malany, Satyamaheshwar Peddibhotla, Paul Mitchell Hershberger, Patrick Maloney, Edward Hampton Sessions, Jr.
-
Publication number: 20220402908Abstract: Provided herein are small molecule inhibitors of CXCR6 receptor, compositions comprising the compounds, and methods of using the compounds and compositions. The compounds are 9-azbicyclo[3.3.1]nonane or 9-diazbicyclo[3.3.1]nonane derivatives, whose synthesis is also described. Also provided are method of treating a disease or condition (such as, cancer) mediated by CXCR6/CXCL16 signaling pathway in a mammal.Type: ApplicationFiled: July 7, 2020Publication date: December 22, 2022Inventors: Satyamaheshwar PEDDIBHOTLA, Paul M. HERSHBERGER, Richard Jason KIRBY, Siobhan MALANY, Layton H. SMITH, Patrick R. MALONEY, Hampton SESSIONS, Daniela DIVLIANSKA, Anthony B. PINKERTON
-
Publication number: 20220064133Abstract: A method and apparatus for transferring an image of predetermined length onto a substrate by selective energization of a row of printing elements in a printhead of a printing apparatus. Operational characteristics of the printing apparatus are determined, and the image is rendered such that the number of rows of the pixels in the rendered image is no greater than the maximum number of rows of pixels which can be printed in the length of the image given the operational characteristics of the printing apparatus. Additional rows of pixels may be printed between pairs of rows of printed which correspond to consecutive rows in the rendered image. The pixel content of each additional row is a function of the pixel content of the adjacent pairs of rows.Type: ApplicationFiled: August 12, 2019Publication date: March 3, 2022Inventors: Otto PHANSTIEL, IV, Holly MOOTS, Patrick MALONEY, Paul HERSHBERGER, Satyamaheshwar PEDDIBHOTLA
-
Patent number: 11261164Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: GrantFiled: January 14, 2020Date of Patent: March 1, 2022Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
-
Publication number: 20210300882Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.Type: ApplicationFiled: June 8, 2021Publication date: September 30, 2021Applicant: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
-
Patent number: 11028061Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.Type: GrantFiled: July 27, 2016Date of Patent: June 8, 2021Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
-
Publication number: 20200354324Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: ApplicationFiled: January 14, 2020Publication date: November 12, 2020Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
-
Patent number: 10584103Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: GrantFiled: September 24, 2018Date of Patent: March 10, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
-
Publication number: 20190023665Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: ApplicationFiled: September 24, 2018Publication date: January 24, 2019Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
-
Patent number: 10118902Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: GrantFiled: June 24, 2015Date of Patent: November 6, 2018Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
-
Publication number: 20180222874Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.Type: ApplicationFiled: July 27, 2016Publication date: August 9, 2018Applicant: Sanford Bumham Prebys Medical Discovery ImstituteInventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
-
Patent number: 9868707Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: GrantFiled: December 19, 2013Date of Patent: January 16, 2018Assignees: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, DUKE UNIVERSITYInventors: Anthony Pinkerton, Patrick Maloney, Paul Hershberger, Satyamaheshwar Peddibhotla, Michael Hedrick, Lawrence Barak, Marc Caron
-
Publication number: 20170240514Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: ApplicationFiled: June 24, 2015Publication date: August 24, 2017Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
-
Publication number: 20150329497Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: ApplicationFiled: December 19, 2013Publication date: November 19, 2015Applicant: DUKE UNIVERSITYInventors: Anthony PINKERTON, Patrick MALONEY, Paul HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Michael HEDRICK, Lawrence BARAK, Marc CARON
-
Patent number: 7858808Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.Type: GrantFiled: January 26, 2010Date of Patent: December 28, 2010Assignee: Board of Trustees of Michigan State UniversityInventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
-
Publication number: 20100204260Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.Type: ApplicationFiled: January 26, 2010Publication date: August 12, 2010Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
-
Patent number: 7652056Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.Type: GrantFiled: April 6, 2005Date of Patent: January 26, 2010Assignee: Board of Trustees of Michigan State UniversityInventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
-
Patent number: 7345078Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants.Type: GrantFiled: May 30, 2003Date of Patent: March 18, 2008Assignee: The Board of Trustees of Michigan State UniversityInventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
-
Publication number: 20050192330Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.Type: ApplicationFiled: April 6, 2005Publication date: September 1, 2005Applicant: Michigan State UniversityInventors: Jetze Tepe, Satyamaheshwar Peddibhotla